Post by LISAvienna

LISAvienna featuring Cutanos GmbH: Learn more about the company's USP, why it has been founded in Vienna and what role KHAN Technology Transfer Fund I plays in this. Robert Wawrzinek, co-founder and CEO of Cutanos, summarizes: “We have developed a unique tool that allows us to deliver antigens to specific immune cells in the skin with exceptional precision. This approach leverages a specialized ligand that functions like an address tag, recognized exclusively by Langerhans cells - a subtype of dendritic cells crucial for regulating immune responses. By targeting delivery to these cells, we maximize the efficiency of active ingredients, minimizing loss and enhancing safety. Depending on the application, we can either stimulate the immune system or promote immune tolerance. As our target cells reside in the skin, painless drug delivery is possible.” LISAvienna's article covers the following topics: - From Germany to Vienna: Professor comes with a start-up - Langerhans Cell Targeted Delivery System (LC-TDS) - KHAN-I driving innovation in early-stage projects - Expertise and money to guide the way - Proof of concept and validation - Overcoming challenges together Christoph Rademacher | Michael Krebs | Johannes Bange | Peter Nussbaumer | Johannes Sarx | Anna Weihs | Tanja Spennlingwimmer | Brigitte Tempelmaier | Philipp Hainzl Austria Wirtschaftsservice | LISA - Life Science Austria | Wirtschaftsagentur Wien | ViennaBusiness | VIENNA REGION | Business Location | Vienna BioCenter | FFG Austrian Research Promotion Agency | ABA - INVEST in AUSTRIA | wings4innovation GmbH | xista science ventures | HTGF | High-Tech Gründerfonds | Max Planck Society | Pfizer | Biomedical Advanced Research and Development Authority (BARDA) | Institute of Science and Technology Austria | University of Vienna